It is concluded that EAM-2201 has the likely to result in in vivo pharmacokinetic drug interactions when co-administered with substrates of CYP2C8, CYP3A4 and UGT1A3, and is evaluated in pooled human liver microsomes. Likely metabolites with the cannabimimetic agent JWH-018 had been synthesised, characterised to probe for their in vivo https://hemalchem.com/product-category/am-series/